&w=3840&q=100)
Anthem Biosciences IPO to list on July 21: Here's what latest GMP hints at
Ahead of the listing, the unlisted shares of Anthem Biosciences were exchanging hands at around ₹713 per share, reflecting a grey market premium (GMP) of ₹143 per share or nearly 25.09 per cent over the issue price of ₹570 per share, showed the sources that track unofficial market activities.
Should the current grey market trends sustain, Anthem Biosciences shares may list on the BSE and NSE at around ₹713 (issue price + GMP). Thus, investors who have been allotted Anthem Biosciences shares can expect a gain of over 25 per cent per share upon listing. That said, since the GMP is an unregulated and unofficial indicator, investors should not consider it a reliable measure of the company's actual market performance.
Anthem Biosciences IPO details
The public offering of Anthem Biosciences, estimated at ₹3,395 crore, comprised entirely an offer-for-sale (OFS) with promoters and shareholders divesting up to 59.6 million equity shares. Anthem Biosciences IPO was available for subscription from July 14, 2025 till July 16, 2025.
Offered at a price band of ₹540–570 with a lot size of 26 shares, it received strong demand from investors, getting oversubscribed by 63.86 times, riding on the back of qualified institutional buyers (QIBs), who bid for 182.65 times the category reserved for them, showed the NSE data.
In its RHP papers, Anthem Biosciences mentioned that it will not use any proceeds from the public issue, and it will be given to the promoters and shareholders selling their stakes through the OFS.
About Anthem Biosciences
Anthem Biosciences (ABL) is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO). With fully integrated operations spanning drug discovery, development, and manufacturing, the company helps drug companies develop and produce medicines.
It works with a wide range of global clients, from small biotech firms to big pharma companies, across 44 countries including the US., Europe, and Japan.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
2 hours ago
- Mint
Upcoming IPO: Ashish Kacholia-owned Sahajanand Medical Technologies files DRHP for public issue launch
Upcoming IPO: Medical devices company Sahajanand Medical Technologies has filed its draft red herring prospectus (DRHP) with the capital markets regulator, the Securities and Exchange Board of India (Sebi), on Friday, July 25, 2025. Founded by Dhirajlal Kotadia in 2001, Sahajanand Medical Technologies (SMT) Limited specialises in advanced medical devices in vascular and structural heart intervention. Ashish Kacholia, Samara Capital Markets Holding Limited, Kotak Pre-IPO Opportunities Fund and Plutus Wealth Management LLP are the major shareholders in the company. According to the DRHP filing, the company is offering a book-built initial public offering (IPO) with an entirely offer for sale (OFS) component. The company proposed to make an offer-for-sale of up to 2,76,44,231 equity shares to shareholders with a face value of Re 1 apiece. The offer also provides a discounted subscription reservation for eligible employees within the employee reservation section. The public issue consists of stakes of up to 27,00,000 equity shares each of Shree Hari Trust and Dhirajkumar Savjibhai Vasoya, around 1,29,58,126 equity shares by Samara Capital Markets Holding Limited, up to 26,15,750 equity shares by Kotak Pre-IPO Opportunities Fund, and up to 66,70,355 equity shares by NHPEA Sparkle Holding B.V. The offer is conducted through a book-building process, with up to 50% allocated to qualified institutional buyers and at least 15% and 35% assigned to non-institutional and retail individual bidders, respectively, according to the draft papers. The equity shares are proposed to be listed on the NSE and BSE. The book-running lead managers for the public issue are Motilal Oswal Investment Advisors, Avendus Capital Private, HSBC Securities and Capital Markets (India), and Nuvama Wealth Management. MUFG Intime India is the registrar. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions, as market conditions can change rapidly, and circumstances may vary.
Business Standard
3 hours ago
- Business Standard
Reliance Infra reports turnaround Q1 PAT to Rs 60 cr
Reliance Infrastructure reported a consolidated net profit of Rs 59.84 crore in Q1 FY26, compared to a net loss of Rs 233.74 crore posted in Q1 FY25. Revenue from operations fell 17.86% to Rs 5,907.82 crore in the quarter ended 30 June 2025. Total expenses declined 4.84% to Rs 6,469.81 crore in Q1 FY26 over Q1 FY25. During the quarter, the cost of power purchased stood at Rs 4,360.23 crore (down 8.12% YoY), while employee benefits expense was Rs 297.90 crore (up 5.97% YoY). The company reported a profit before exceptional items and tax of Rs 286.67 crore in Q1 FY26, compared to a pre-tax loss of Rs 78.29 crore reported in the same quarter of the previous year. The company reported exceptional items of Rs 0.62 crore in Q1 FY26. EBITDA stood at Rs 1,494 crore in Q1 FY26, registering a 29% YoY growth compared to Rs 1,155 crore in Q1 FY25. Reliance Infrastructure is one of the largest infrastructure companies, developing projects through various Special Purpose Vehicles (SPVs) across several high-growth sectors such as power, roads, and metro rail in the infrastructure space, as well as in the defence sector. It is also a major player in providing Engineering and Construction (E&C) services for power, infrastructure, metro, and road projects. The scrip hit a 5% lower circuit and closed at Rs 342.05 on Friday, 25 July 2025, on the BSE.
Business Standard
3 hours ago
- Business Standard
Chennai Petro posts net loss of Rs 57 crore in Q1; clocks GRM of $3.22 per barrel
Chennai Petroleum Corporation (CPCL) has reported a standalone net loss of Rs 57 crore in Q1 FY26 as compared with net profit of Rs 343 crore recorded in Q1 FY25. For the quarter ended on 30 June 2025, revenue from operations stood at Rs 18,683 crore, down 8.24% YoY. The company posted a pre-tax profit of Rs 80 crore in Q1 FY26 as against a pre-tax profit of Rs 470 crore registered in Q1 FY25. The gross refining margin (GRM) for the quarter was $3.22 per barrel, down from $6.33 per barrel in the corresponding period last year. This decline was primarily due to inventory losses on crude oil and finished products of US$ 1.9 per barrel as against inventory gain of US$ 1.1 per barrel in Q1 of the previous financial year. CPCL has recorded a crude throughput of 2.981 million metric tonnes (MMT) for the quarter ended 30 June 2025, as compared to 2.830 MMT in the corresponding quarter of the previous financial year, with a capacity utilisation of 114%. This was further supported by best-ever distillate yield of about 80% and excellent performance on energy front, demonstrating continued operational efficiency. On a consolidated basis, CPCL has posted a net loss of Rs 40 crore in Q1 FY2025-26 as against a net profit of Rs 357 crore. Net sales declined by 13.4% YoY to Rs 14,812.23 crore during the period under review. Chennai Petroleum Corporation is in the business of refining crude oil to produce & supply various petroleum products and manufacture and sell lubricating oil additives. The scrip tumbled 9.68% to end at Rs 687.35 on the BSE yesterday.
